CN114099666B - FcγRIIB（CD32B）和CD20特异性抗体的组合应用 - Google Patents

FcγRIIB（CD32B）和CD20特异性抗体的组合应用 Download PDF

Info

Publication number
CN114099666B
CN114099666B CN202110959352.XA CN202110959352A CN114099666B CN 114099666 B CN114099666 B CN 114099666B CN 202110959352 A CN202110959352 A CN 202110959352A CN 114099666 B CN114099666 B CN 114099666B
Authority
CN
China
Prior art keywords
seq
fcyriib
cells
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110959352.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114099666A (zh
Inventor
马克·克拉格
M·格兰尼
阿里·鲁加尼安
斯蒂芬·贝尔斯
P·约翰逊
肖恩·林
比约恩·弗伦多斯
英格丽德·泰格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Publication of CN114099666A publication Critical patent/CN114099666A/zh
Application granted granted Critical
Publication of CN114099666B publication Critical patent/CN114099666B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202110959352.XA 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用 Active CN114099666B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1013989.7A GB201013989D0 (en) 2010-08-20 2010-08-20 Biological materials and methods of using the same
GB1013989.7 2010-08-20
CN201180040351XA CN103080131A (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
PCT/GB2011/051572 WO2012022985A1 (en) 2010-08-20 2011-08-19 Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180040351XA Division CN103080131A (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用

Publications (2)

Publication Number Publication Date
CN114099666A CN114099666A (zh) 2022-03-01
CN114099666B true CN114099666B (zh) 2025-05-02

Family

ID=42984443

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202110959353.4A Active CN114099667B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN202110959352.XA Active CN114099666B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN202110959481.9A Pending CN114099669A (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN201710789909.3A Active CN107670034B (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
CN202110959354.9A Active CN114099668B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN201180040351XA Pending CN103080131A (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
CN202110959355.3A Active CN114099702B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110959353.4A Active CN114099667B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202110959481.9A Pending CN114099669A (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN201710789909.3A Active CN107670034B (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
CN202110959354.9A Active CN114099668B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用
CN201180040351XA Pending CN103080131A (zh) 2010-08-20 2011-08-19 FcγRIIB(CD32B)和CD20特异性抗体的组合应用
CN202110959355.3A Active CN114099702B (zh) 2010-08-20 2011-08-19 FcγRIIB（CD32B）和CD20特异性抗体的组合应用

Country Status (17)

Country Link
US (4) US10525129B2 (enExample)
EP (2) EP3263602A1 (enExample)
JP (2) JP6215704B2 (enExample)
KR (1) KR101948609B1 (enExample)
CN (7) CN114099667B (enExample)
AU (1) AU2011290503B2 (enExample)
CA (1) CA2808744C (enExample)
DK (1) DK2606068T3 (enExample)
ES (1) ES2653685T3 (enExample)
GB (1) GB201013989D0 (enExample)
HU (1) HUE037478T2 (enExample)
NO (1) NO2606068T3 (enExample)
PL (1) PL2606068T3 (enExample)
PT (1) PT2606068T (enExample)
RU (2) RU2769949C2 (enExample)
SI (1) SI2606068T1 (enExample)
WO (1) WO2012022985A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
RU2015125349A (ru) * 2012-11-29 2017-01-10 Байер Хелскеа Ллк МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС)
ES2730690T3 (es) * 2012-12-07 2019-11-12 Suppremol Gmbh Estratificación y tratamiento de pacientes que padecen púrpura trombocitopénica idiopática
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
EP2833139A1 (en) * 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
EP3575312A1 (en) 2014-01-27 2019-12-04 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CA2975660A1 (en) * 2015-03-16 2016-09-22 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Trispecific binding molecules for treating hbv infection and associated conditions
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
UY37030A (es) 2015-12-18 2017-07-31 Novartis Ag Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
AU2017373962B2 (en) 2016-12-07 2022-03-31 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
EP3573640A4 (en) * 2017-01-30 2021-04-28 The Ohio State Innovation Foundation PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
CN108823211A (zh) * 2018-05-04 2018-11-16 中国医学科学院基础医学研究所 一种cd19核酸适配体及其应用
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
AU2020315163B2 (en) * 2019-07-17 2025-11-20 Bioinvent International Ab Antibody combinations for treatment of cancer in specific patients
CR20220166A (es) * 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP3919077A1 (en) 2020-06-04 2021-12-08 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
TW202210103A (zh) 2020-06-04 2022-03-16 瑞典商生物創新國際有限公司 治療系統、方法及用途
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
US20230399375A1 (en) 2022-04-15 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
WO2023240064A1 (en) 2022-06-08 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002933A2 (en) * 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
IL149500A0 (en) * 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
JP4459810B2 (ja) * 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US20050260213A1 (en) 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005018669A1 (en) * 2003-08-18 2005-03-03 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
ES2371468T3 (es) 2003-11-26 2012-01-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. SUSTANCIA QUE SE UNE AL RECEPTOR HUMANO llb MEDIANTE Fc DE IgG (Fc? Rllb).
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CN101522714A (zh) * 2004-05-20 2009-09-02 圣玛莉医院国民健康保险基金 用于治疗过敏性疾病的IgE重定位、功能性改变分子（ERFAM）
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CA2590935C (en) * 2004-12-15 2014-09-30 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US20120030144A1 (en) * 2007-11-08 2012-02-02 Pikamab, Inc. Methods for doing business using biomarkers
EP2234641B1 (en) * 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b
US20110268753A1 (en) 2009-01-08 2011-11-03 The Uab Research Foundation Process for regulating immune response
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002933A2 (en) * 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof

Also Published As

Publication number Publication date
KR20140005866A (ko) 2014-01-15
EP3263602A1 (en) 2018-01-03
KR101948609B1 (ko) 2019-02-15
CA2808744C (en) 2023-03-07
CN114099669A (zh) 2022-03-01
ES2653685T3 (es) 2018-02-08
WO2012022985A1 (en) 2012-02-23
US20210346498A1 (en) 2021-11-11
HUE037478T2 (hu) 2018-08-28
US20230381310A1 (en) 2023-11-30
RU2013112345A (ru) 2014-09-27
JP2013537547A (ja) 2013-10-03
US20130251706A1 (en) 2013-09-26
CN114099666A (zh) 2022-03-01
CN103080131A (zh) 2013-05-01
GB201013989D0 (en) 2010-10-06
DK2606068T3 (da) 2017-11-20
JP2016138129A (ja) 2016-08-04
EP2606068A1 (en) 2013-06-26
JP6215704B2 (ja) 2017-10-18
NO2606068T3 (enExample) 2018-02-24
CN114099702A (zh) 2022-03-01
AU2011290503A1 (en) 2013-03-07
CN114099668A (zh) 2022-03-01
CN114099702B (zh) 2024-08-27
RU2017143633A3 (enExample) 2021-01-29
RU2017143633A (ru) 2019-02-14
AU2011290503B2 (en) 2015-09-03
PT2606068T (pt) 2017-12-29
CN107670034B (zh) 2021-07-20
SI2606068T1 (en) 2018-01-31
US20200069798A1 (en) 2020-03-05
CN114099667A (zh) 2022-03-01
US11623005B2 (en) 2023-04-11
CN107670034A (zh) 2018-02-09
JP6421140B2 (ja) 2018-11-07
RU2769949C2 (ru) 2022-04-11
CN114099667B (zh) 2025-10-21
CN114099668B (zh) 2025-10-17
EP2606068B1 (en) 2017-09-27
PL2606068T3 (pl) 2018-03-30
CA2808744A1 (en) 2012-02-23
US10525129B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
CN114099666B (zh) FcγRIIB（CD32B）和CD20特异性抗体的组合应用
AU2015261422B2 (en) Medicaments, uses and methods
HK40067401A (en) Combined use of fcγriib(cd32b) and cd20 specific antibodies
HK40066734A (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40066735A (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40067401B (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40074577A (en) Medicaments, uses and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066736

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant